Last reviewed · How we verify
Individual Antithymocyte globulin
Antithymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells, thereby suppressing cell-mediated immune responses.
Antithymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells, thereby suppressing cell-mediated immune responses. Used for Prevention of acute rejection in organ transplantation, Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment.
At a glance
| Generic name | Individual Antithymocyte globulin |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Drug class | Polyclonal antithymocyte globulin |
| Target | T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
ATG is produced by immunizing animals (typically rabbits or horses) with human thymocytes, generating a heterogeneous mixture of antibodies against T-cell antigens. These antibodies bind to circulating and tissue-resident T lymphocytes, leading to their destruction through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This profound T-cell depletion reduces rejection responses in transplantation and modulates autoimmune conditions.
Approved indications
- Prevention of acute rejection in organ transplantation
- Treatment of aplastic anemia
- Graft-versus-host disease (GVHD) prophylaxis and treatment
Common side effects
- Cytokine release syndrome
- Fever and chills
- Thrombocytopenia
- Leukopenia
- Serum sickness
- Infection (due to immunosuppression)
Key clinical trials
- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (PHASE2)
- Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE3)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE2)
- Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE4)
- Stem Cell Transplantation for Stiff Person Syndrome (SPS) (PHASE1, PHASE2)
- Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (PHASE3)
- Stem Cell Transplant for Bone Marrow Failure Syndromes (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |